Burning Rock Biotech (BNR) Payables (2019 - 2026)

Burning Rock Biotech's Payables history runs 8 years deep, the most recent figure standing at $2.7 million for Q1 2026.

• In Q1 2026, Payables fell 46.32% year-over-year to $2.7 million; the TTM figure through Mar 2026 stood at $2.7 million (down 46.32% YoY), while the FY2025 annual figure was $5.8 million, up 23.9% from the prior year.
• Payables for Q1 2026 stood at $2.7 million, down from $5.8 million in the prior quarter.
• The five-year high for Payables was $15.6 million in Q1 2022, with the low at $2.7 million in Q4 2023.
• The 5-year median for Payables is $4.6 million (2025), against an average of $5.5 million.
• The sharpest annual moves came in 2022 and 2023: Payables jumped 100.73% in 2022, then plunged 76.86% in 2023.
• Burning Rock Biotech's Payables stood at $7.4 million in 2022, then plunged by 63.94% to $2.7 million in 2023, then jumped by 78.73% to $4.8 million in 2024, then advanced by 21.91% to $5.8 million in 2025, then tumbled by 53.64% to $2.7 million in 2026.
• Business Quant data shows BNR's Payables at $2.7 million in Q1 2026, $5.8 million in Q4 2025, and $4.8 million in Q3 2025.